Cargando…

Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics

Acute myelogenous leukemia (AML) is an aggressive hematological malignancy. The pathophysiology of the disease depends on cytogenetic abnormalities, gene mutations, aberrant gene expressions, and altered epigenetic regulation. Although new pharmacological agents have emerged during the last years, t...

Descripción completa

Detalles Bibliográficos
Autor principal:	Reikvam, Håkon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408594/ https://www.ncbi.nlm.nih.gov/pubmed/32664684 http://dx.doi.org/10.3390/cells9071677

Ejemplares similares

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis
por: Cacic, Daniel, et al.
Publicado: (2021)

Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia
por: Steinfeld, Peter Ferkis, et al.
Publicado: (2021)

Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation
por: Xu, Xuefen, et al.
Publicado: (2017)

Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells
por: Basappa, Basappa, et al.
Publicado: (2023)

Author Correction: Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/ NF-κB inactivation
por: Xu, Xuefen, et al.
Publicado: (2021)

Retraction Note: Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation
por: Xu, Xuefen, et al.
Publicado: (2022)

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
por: Brenner, Annette K., et al.
Publicado: (2016)

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia
por: Guo, Naxin, et al.
Publicado: (2019)

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
por: Lu, Zhongzheng, et al.
Publicado: (2010)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism
por: Nepstad, Ina, et al.
Publicado: (2018)

Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
por: Lu, Zhongzheng, et al.
Publicado: (2021)

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
por: Nepstad, Ina, et al.
Publicado: (2020)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition
por: Brattås, Marte Karen, et al.
Publicado: (2022)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2023)

Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia
Publicado: (1978)

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2013)

Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro Stress
por: Ryningen, Anita, et al.
Publicado: (2012)

Familial Adenomatous Polyposis Complicated by Acute Myelogenous Leukemia
por: Alkofahi, Ala A, et al.
Publicado: (2020)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Acute Myelogenous Leukemia Mimicking Fulminant Periorbital Cellulitis
por: Bagheri, Abbas, et al.
Publicado: (2013)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

NF-κB: A Druggable Target in Acute Myeloid Leukemia
por: Di Francesco, Barbara, et al.
Publicado: (2022)

Autocrine stimulation of interleukin 1 beta in acute myelogenous leukemia cells
Publicado: (1987)

Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells
por: Ji, Qing, et al.
Publicado: (2016)

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2022)

PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway
por: Hou, Shuaibing, et al.
Publicado: (2023)

Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms
por: Brenner, Annette K., et al.
Publicado: (2014)

Genital Sweet's Syndrome in a patient with Acute Myelogenous Leukemia
por: Ensley, Daniel, et al.
Publicado: (2020)

Spinal epidural granulocytic sarcoma preceding acute myelogenous leukemia.
por: Kook, H., et al.
Publicado: (1992)

How mRNA is misspliced in acute myelogenous leukemia (AML)?
por: Mohamed, Aminetou Mint, et al.
Publicado: (2014)

Severe Intracranial Hemorrhage at Initial Presentation of Acute Myelogenous Leukemia
por: Balmages, Amanda, et al.
Publicado: (2018)

Acute Myelogenous Leukemia as a Rare Cause of Duodenal Ulcers
por: Sobotka, Lindsay A., et al.
Publicado: (2019)

Rhizopus microsporus typhlitis in a patient with acute myelogenous leukemia
por: Trybula, Marcus, et al.
Publicado: (2021)

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
por: Ahmad, Rita, et al.
Publicado: (2021)

Management of chronic myelogenous leukemia with COVID-19 and hepatitis B
por: Yu, Tian, et al.
Publicado: (2023)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells
por: dos Santos, Nuno R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_55pfkbktclee5hm2kjm8almfau